Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.

about

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.

Item

http://www.wikidata.org/entity/Q49292353

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.

@en

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.

@nl

type

Item

label

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.

@en

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.

@nl

prefLabel

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.

@en

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide.

@nl

P1476

Stevens-Johnson syndrome/toxic epidermal necrolysis associated with zonisamide

@en

P2093

Kimberly Mancl

http://www.w3.org/2001/XMLSchema#string

P2860

High-level human herpesvirus-6 viremia associated with onset of Stevens-Johnson syndrome: report of two cases.

Safety and Efficacy of Zonisamide in Patients with Epilepsy: A Post-Marketing Surveillance Study

Clinical pharmacology and mechanism of action of zonisamide.

Predicting possible zonisamide hypersensitivity syndrome.

The Use of Zonisamide for the Treatment of Psychiatric Disorders: A Systematic Review.

Score of Toxic Epidermal Necrosis Predicts the Outcomes of Pediatric Epidermal Necrolysis.

Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects.

A cautionary note when using zonisamide in youths: a case report of association with toxic epidermal necrolysis.

Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6.

Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial.

P304

258-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1002/CCR3.1288

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Lucia Seminario-Vidal

Karina L Vivar

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29445458

http://www.w3.org/2001/XMLSchema#string

P932

5799627

http://www.w3.org/2001/XMLSchema#string